No Data
No Data
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $78
Avidity Biosciences' Promising Developments in DMD Treatment and Strategic Preparations for Future Success
Forecasting The Future: 13 Analyst Projections For Avidity Biosciences
Scotiabank Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
Optimistic Buy Rating for Avidity Biosciences Driven by Promising DMD Treatment and Strategic Expansion Plans
Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025